The Berkshire Hathaway exit from UnitedHealth Group is being treated as the story. It isn't. The real story is what happened after: a 45% rally in six weeks that compressed the very valuation discount that once made this stock worth buying.
Berkshire sold its entire 5 million-share position during the first quarter, its first portfolio move under new CEO Greg Abel. The stock dipped 4% on the news Monday. Retail traders on Stocktwits dismissed the exit - arguing Abel sold between $250 and $290, missing the subsequent surge toward $400. The mockery of Berkshire's timing is entertaining but irrelevant to the investment case. The question now is whether UNH at roughly $365 to $370 represents a buying opportunity or a stock that has already run to its fair value.
The operating turnaround is real
UnitedHealth's Q1 2026 quarter was genuinely strong. Revenue of $111.7 billion grew 2% year-over-year. Adjusted earnings of $7.23 per share beat the $6.59 estimate by a wide margin. The medical care ratio... improved to 83.9% from 84.8%... well below the 85.5% Wall Street expected. That matters because a falling medical care ratio means UnitedHealth is retaining more of every dollar in premium as profit. Operating cash flow was $8.9 billion for the quarter.
Management raised full-year 2026 adjusted EPS guidance to above $18.25... above the Street's $17.78 consensus. The company is investing $1.5 billion into AI... targeting $1 billion in cost savings and an operating cost ratio reduction to 12.8%, down from 13.8%. CFO Wayne DeVeydt said AI is advancing "faster than people can appreciate or understand," and the company claims it has already deployed over 1,000 AI use cases internally, avoiding 15 million calls and processing hundreds of millions of claims.
None of this is narrative. The margin improvements are showing up in the numbers.
The data point nobody wants to discuss
UnitedHealth lost 965,000 Medicare members in Q1 2026. That is nearly a million members walking door, in a segment that is supposed to be the structural growth engine of the business. The competitor narrative around Medicare Advantage reimbursement pressure turned out to be overstated - reimbursement rates ended up better than feared - but member attrition on that scale is a demand-side problem that AI cost savings don't fix.
You can improve your medical care ratio and still be losing the customers you need to grow into. UnitedHealth's full-year revenue guidance remains above $439 billion, which is only 1.8% growth. On a $431 billion revenue base in 2025, that is deceleration, not acceleration. The growth story has friction.
Valuation: the discount closed before the Berkshire headline
The stock trades at roughly 21 times forward earnings on the $18.25 EPS guidance. Trailing P/E sits around 18.7. These are not cheap numbers for a company growing revenue under 2% and losing nearly a million members in its most strategic segment. The valuation that made UNH a compelling buy - the post-selloff multiple compression that followed years of reputational and regulatory pressure - is gone. The stock has itself.
When Berkshire built its position in Q2 2025, UNH was trading through one of its sharpest selloffs in years. The risk was real: Medicare reimbursement cuts, Optum Health margin pressure, regulatory scrutiny. The market priced those fears into a multiple that created margin of safety. That multiple has expanded roughly 45% since the February lows. The risks that justified the discount have eased - but the discount itself has vanished too.
The AI investment: real savings, not a growth story
The $1.5 billion AI investment is a cost-reduction program, not a revenue driver. UnitedHealth claims a two-to-one return on these investments - meaning every dollar spent returns $2 in savings. If that holds, it supports margin expansion and free cash flow. But it does not create the kind of top-line acceleration that would justify paying a premium multiple. AI at UnitedHealth is margin leverage, not growth leverage. There is a difference when you are evaluating whether a stock that has already surged 45% is worth adding to.
What would make this a buy again
Three things would reset the risk/reward in favor of a new position: a pullback that reopens the valuation gap (think $320 to $330 range, where the forward multiple falls back toward 17-18x); evidence that Medicare member stabilization or growth is underway in Q2; or a meaningful beat on the $439 billion revenue guidance that signals the growth deceleration was temporary.
None of those conditions are met today.
Investor takeaway: Hold
UnitedHealth is executing a genuine margin turnaround with real AI-driven cost improvements. The medical care ratio is moving in the right direction. The earnings guidance raise is meaningful. But the stock has already priced all of that in. The 45% rally closed the valuation discount that made this stock actionable. The 965,000 Medicare member loss is a headwind that cost savings alone cannot overcome.
This is not a buy-into-the-dip moment. The dip was 4%. The rally was 45%. At roughly 21 times forward earnings, with sub-2% revenue growth and significant Medicare member attrition, the math doesn't support new money here. If you own it, the operating improvements justify holding. If you don't, the valuation reset that made UNH worth buying is over. Wait for the next one.